

CURRICULUM VITAE

Personal Information

First name / Surname: **Maria Carmina Castiello**
Date of birth: June 9th, 1983 Nationality: Italian
e-mail: castiello.mariacarmina@hsr.it, mariacarmina.castiello@cnr.it

Education

Dates : 12/2009 - 4/2013
Title of qualification awarded : **PhD in Molecular Medicine** (section of "Basic and Applied Immunology")
Institution : Vita-Salute San Raffaele University of Milan, Italy
Thesis Title : **"Dissection of cellular and molecular defects of B cells and platelets before and after gene therapy in Wiskott-Aldrich Syndrome"**
Supervisor : Dr. Anna Villa - San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), Milan, Italy
Director of Study : Prof. Dr. Alessandro Aiuti - San Raffaele Hospital; SR-Tiget; Vita-Salute San Raffaele University, Milan, Italy
Second Supervisor : Prof. Dr. Simon Fillatreau - Deutsches Rheuma-Forschuns Zentrum, a Leibniz Institute, Berlin, Germany

Dates : 1/2006 - 10/2007
Title of qualification awarded : **Master of Science Degree in Medical Biotechnology** (medical curriculum)
Institution : University of Naples Federico II, Italy
Thesis Title : **"Effect of IGF-1 treatment on endothelial vascular dysfunction: immunohistochemical analysis in a balloon injury rat model"**
Supervisor : Prof. Antonio Cittadini - Department of Clinical Medicine and Cardiovascular Science, University of Naples "Federico II", Naples, Italy
Final mark : 110/110 CUM LAUDE

Dates : 10/2001 - 12/2005
Title of qualification awarded : **Bachelor of Science Degree in Medical Biotechnology** (medical curriculum)
Institution : University of Naples Federico II, Italy
Thesis Title : **"Bcl-xL cardiac gene therapy attenuates heart failure progression in a pressure overload rat model"**
Supervisor : Prof. Antonio Cittadini - Department of Clinical Medicine and Cardiovascular Science, University of Naples "Federico II", Naples, Italy
Final mark : 106/110

Dates : 1996 - 2001
Title of qualification awarded : **High School Diploma**
Institution : Liceo Scientifico F. Brunelleschi, Afragola, Naples, Italy

Work Experience and Training

November 2019 – present

Ricercatore III livello - *Institute of Genetics and Biomedical Research (IRGB), CNR-UOS Milan CNR, Italy.*

Senior Post-Doc - *Pathogenesis and Treatment of Immune and Bone diseases lab, San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), Milan, Italy.*

- 1) Study of innovative therapeutic approaches based on gene editing of hematopoietic stem cells in Severe Combined Immunodeficiency forms due to RAG defects and in Hyper-IgM Syndrome caused by CD40L deficiency.
- 2) Development of novel conditioning regimens based on the non-genotoxic immunotoxin CD45-saporin in RAG1 deficiency.
- 3) Study of the role of Wiskott-Aldrich Syndrome protein (WASp) in the cellular and molecular biology of follicular helper T cells and humoral immunity analyzing samples from patients with mutations in WASp before and after hematopoietic stem cell transplantation or gene therapy.
- 4) Monitoring of cellular and molecular defects of B lymphocytes and platelets before and after lentiviral vector-mediated gene therapy in Wiskott-Aldrich Syndrome.

October 2017 – November 2019

Senior Post-Doc - *Pathogenesis and Treatment of Immune and Bone diseases lab, San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), Milan, Italy.*

- 1) Study of innovative therapeutic approaches based on gene editing of hematopoietic stem cells in Severe Combined Immunodeficiency forms due to RAG defects and in Hyper-IgM Syndrome caused by CD40L deficiency.

- 2) Development of novel conditioning regimens based on the non-genotoxic immunotoxin CD45-saporin in RAG1 deficiency.
- 3) Study of the role of Wiskott-Aldrich Syndrome protein (WASp) in the cellular and molecular biology of follicular helper T cells and humoral immunity analyzing samples from patients with mutations in WASp before and after hematopoietic stem cell transplantation or gene therapy.
- 4) Monitoring of cellular and molecular defects of B lymphocytes and platelets before and after lentiviral vector-mediated gene therapy in Wiskott-Aldrich Syndrome.

May 2013 - October 2017

Post-Doc Research Fellow - Pathogenesis and Treatment of Immune and Bone diseases lab, San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), Milan, Italy.

- 1) Development of gene therapy and gene editing technologies to treat Severe Combined Immunodeficiency due to RAG1 and RAG2 defects.
- 2) Immunological characterization of a mouse model of Hyper-IgM Syndrome caused by CD40L deficiency.
- 3) Study of cellular and molecular defects of B lymphocytes and platelets caused by the absence of Wiskott-Aldrich Syndrome protein (WASp) in humans and mouse models.

June 2008 - April 2013

Post Graduate Fellow and PhD Student - Pathogenesis and Treatment of Immune and Bone diseases lab, San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) - Vita-Salute San Raffaele University, Milan, Italy.

- 1) Characterization of B cell defect in the absence of Wiskott-Aldrich Syndrome protein.
- 2) Study of molecular and pathological events leading to thrombocytopenia in the Wiskott-Aldrich Syndrome, in human and knock-out murine models.

August 2011 - November 2011

Visiting Fellow - Molecular Immunology lab, Erasmus Medical Center, Rotterdam, The Netherlands.

Phenotypic and molecular analysis of B cells derived from Wiskott-Aldrich Syndrome patients.

January 2006 - May 2008

Internship for Master Thesis and Post Graduate Fellow - Department of Clinical Medicine and Cardiovascular Science, University of Naples "Federico II", Naples, Italy

- 1) Study of the overexpression of Bcl-xL mediated by AAV gene transfer in attenuating pressure-overload cardiac remodeling in a rat model.
- 2) Evaluation of the role of growth factors and stem cells in experimental models of myocardial infarction or hypertrophic cardiopathy by using biomaterials regulating their spatio-temporal delivery.

April 2003 - December 2005

Internship for Bachelor Thesis - Department of Clinical Medicine and Cardiovascular Science, University of Naples "Federico II", Naples, Italy

- 1) Study of the Insulin-like growth factor-1 (IGF-1) effects in the vascular system using a restenosis animal model. Evaluation of both morphometric and molecular modifications that occur in the neointima formation secondary to vascular injury, in presence or in absence of IGF-1 treatment.

Grant

- 1) **Principal Investigator**, Progetto Giovani Ricercatori 2019 (GR-2019-12369050), funded by Italian Ministry of Health. Project: "Innovative pre-transplant conditionings to preserve bone marrow niche and improve the immunological reconstitution in immune dysregulation disorders". Duration: three years; Amount: € 450.00,00.
- 2) **Co-Principal Investigator**, Progetto Giovani Ricercatori 2016 (GR-2016-02365089), funded by Italian Ministry of Health. Project: "Role of follicular helper T cells in the humoral immune alterations in patients with mutations in the Wiskott-Aldrich Syndrome protein before and after hematopoietic stem cell transplantation or gene therapy". Duration: 2018-2021; Amount: € 123.525,00.
- 3) **Co-Investigator**, Progetto Giovani Ricercatori (GR-2013-02358956), funded by Italian Ministry of Health. Project: "Targeted genome editing of the CD40LG gene for the treatment of X-linked hyper-IgM immunodeficiency". Duration: 2016-2019; Amount: € 75.000,00.
- 4) ESID (European Society for Immunodeficiencies) Award for the **medium term fellowship**. Project: "Phenotypic and molecular analysis of B cells derived from Wiskott-Aldrich Syndrome patients". Duration: 08/2011 – 11/2011; Amount: € 3.000,00.

Honors and Award

- 2018 **Best E-Poster Award** (personal grant €250,00), 18th Biennial Meeting of European Society for Immunodeficiencies (ESID) (Lisboa, Portugal)
- 2016 **Excellence in Research Award** and **Meritorious Abstract Travel Award**, 19th Annual Meeting of the American Society of Gene and Cell Therapy, ASGCT (Washington DC, US)
- 2015 **Best Poster Award**, 18th Annual Meeting of the ASGCT (New Orleans, US)
- 2014 **Meritorious Abstract Travel Award**, 17th Annual Meeting of the ASGCT (Washington DC, US)
- 2012 **Oral Abstract Presentation Award**, 15th Biennial Meeting of the ESID (Florence, Italy)
- 2011 Medium term **fellowship Award** (€ 3.000,00), European Society for Immunodeficiencies (ESID)
- 2009 **Travel Award**, 3rd Translational Research in Pediatric Rheumatology Conference (TRIPR-Adaptive Immunity and the Pathogenesis of Rheumatic Disease) (Genoa, Italy)

Participation at National and International Scientific Project

- *European Union's Horizon 2020 research and innovation programme to Anna Villa (Coordinator: Bobby Gaspar) (SCIDNET-666908)*. Project: Developing Genetic medicines for Severe Combined Immunodeficiency (SCID) (1/1/2016 - 31/08/2019).
- *Italian Ministry of Health, Giovani Ricercatori Grant to Marita Bosticardo (GR-2009-1579814)*. Project: B cell reconstitution upon gene therapy in WAS patients from the first clinical trial with lentiviral vectors (01/01/2015 - 31/05/2015).
- *Fondazione Telethon to Anna Villa (TEGSK-WAS)*. Project: Analysis of the restoration of cellular and molecular defects in B cells and platelets upon Lentiviral Hematopoietic Stem Cell Gene Therapy in Patients with Wiskott-Aldrich Syndrome (1/1/2011 - 30/06/2014).
- *Fondazione Telethon to Anna Villa (TGT11A02)*. Project: Cellular and Molecular mechanisms underlying autoimmunity in Wiskott-Aldrich Syndrome (1/1/2009 - 31/12/2010; 01/07/2014 - 31/12/2014; 01/06/2015-31/12/2015).

Main Scientific Communications

- Barcelona, Spain; October, 22th-25th 2019, 27th Annual Meeting of European Society of Gene Therapy (ESGCT). Poster Presentation: "Non-genotoxic conditioning based on immunotoxin CD45-sap promotes an adequate immunological reconstitution in a mouse model of SCID caused by RAG1 defect".
- Lisboa, Portugal; October 24th-27th 2018: 18th Biennial Meeting of European Society for Immunodeficiencies (ESID). **E-Poster Presentation**: "Non-genotoxic conditioning based on immunotoxin CD45-sap promotes an adequate immunological reconstitution in a mouse model of SCID caused by RAG1 defect".
- Dresden, Germany; June 17th- 21th 2018: Keystone Symposia Conference 2018. Poster Presentation: "Suboptimal clearance of pathogens and self-antigens causes B-cell tolerance breakdown in Wiskott-Aldrich Syndrome".
- Washington, US, May 13th-16th 2015 - 19th Annual Meeting of the ASGCT. **Oral Presentation**: "Lentiviral-Mediated Gene Therapy Restores B Cell Homeostasis and Tolerance in Wiskott-Aldrich Syndrome Patients". ISSN 1525-0016
- Riva del Garda, Italy; March 9th-11th 2015: XVIII Scientific Telethon Convention. Poster Presentation: "B-cell reconstitution in Wiskott-Aldrich Syndrome Patients after LV-gene therapy".
- New Orleans, US; May 13th-16th 2015: 18th Annual Meeting of the ASGCT. Poster Presentation: "Lentiviral gene therapy in a preclinical model of Omenn syndrome".
- Stresa, Italy; February 4th 2014: Advanced Cell-based Therapies for the treatment of Primary Immunodeficiency (CELL-PID) Annual Meeting. **Invited Speaker**: "B-cell reconstitution in Wiskott-Aldrich Syndrome Patients after LV-gene therapy".
- Prague, Czech Republic; 19thOct-1stNov 2014: 16th Biennial Meeting of the ESID. Poster Presentation for educational day: "Altered central and peripheral B-cell tolerance checkpoints in Wiskott-Aldrich Syndrome patients".
- Washington DC, US; May 20th-24th 2014: 17th Annual Meeting of the ASGCT. **Oral presentation**: "B cell reconstitution after lentiviral vector-mediated gene therapy in Wiskott-Aldrich Syndrome patients". ISSN: 1525-0016
- Florence, Italy; October 3rd-6th 2012: 15th Biennial Meeting of the ESID. **Oral presentation**: "Defective B-cell development and function in bone marrow and peripheral blood of Wiskott-Aldrich syndrome patients".
- Baltimore, USA; May 7th-11th 2010: American Association Immunology Congress. Poster Presentation: "Characterization of B cell function in Wiskott Aldrich Syndrome". ISSN: 0022-1767
- Genoa, Italy; September 24th-27th 2009: 3rd Translational Research in Paediatric Rheumatology Conference. **Oral presentation**: "Functional characterization of WASp deficient B cells and their role in inducing autoimmunity".
- Stresa, Italy; February 19th-21th 2009: hSR Scientific Retreat (SR2): Poster Presentation: "Unravelling the role of WASp in platelets".
- Naples, Italy; May 2007: 68^o SIC National Meeting. Poster Presentation: "Differential Effect of IGF-1 on the intima

and media in a ballon injury animal model”.

Research Metrics and Publications

Author ID:

SCOPUS Author ID: 35809917800

ResearcherID: K-9767-2016

ORCID_Id: <https://orcid.org/0000-0003-2581-9648>

- Research metrics (Scopus source, January 29th 2021):

h-index: 14

Total Article in Publication List: 26

Total Citations: 1299 by 1044 documents

1. *Modeling, optimization, and comparable efficacy of T cell and hematopoietic stem cell gene editing for treating hyper-IgM syndrome.* Vavassori V, Mercuri E, Marcovecchio GE, **Castiello MC**, Schirolli G, Albano L, Margulies C, Buquicchio F, Fontana E, Beretta S, Merelli I, Cappelleri A, Rancoita PM, Lougaris V, Plebani A, Kanariou M, Lankester A, Ferrua F, Scanziani E, Cotta-Ramusino C, Villa A, Naldini L, Genovese P. *EMBO Mol Med*. 2021 Jan 21:e13545. doi: 10.15252/emmm.202013545.
2. *Efficacy and safety of anti-CD45-saporin as conditioning agent for RAG deficiency.* **Castiello MC**, Bosticardo M, Sacchetti N, Calzoni E, Fontana E, Yamazaki Y, Draghici E, Corsino C, Bortolomai I, Sereni L, Yu H-H, Uva P, Palchoudhuri R, Scadden DT, Villa A, Notarangelo LD. *J Allergy Clin Immunol*. 2020 May 6; S0091-6749(20)30629-1. doi:10.1016/j.jaci.2020.04.033. PMID: 32387109.
3. *Innovative Cell-Based Therapies and Conditioning to Cure RAG Deficiency.* Villa A, Capo V, **Castiello MC**. *Front Immunol*. 2020 Nov 19;11:607926. doi: 10.3389/fimmu.2020.607926. eCollection 2020.
4. *Lentiviral gene therapy corrects platelet phenotype and function in patients with Wiskott-Aldrich syndrome.* Sereni L, **Castiello MC**, Di Silvestre D, Della Valle P, Brombin C, Ferrua F, Cicalese MP, Pozzi L, Migliavacca M, Bernardo ME, Pignata C, Farah R, Notarangelo LD, Marcus N, Cattaneo L, Spinelli M, Giannelli S, Bosticardo M, van Rossem K, D'Angelo A, Aiuti A, Mauri P, Villa A. *J Allergy Clin Immunol*. 2019 Sep;144(3):825-838. doi: 10.1016/j.jaci.2019.03.012. Epub 2019 Mar 27.
5. *Neutrophils drive type I interferon production and autoantibodies in patients with Wiskott-Aldrich syndrome.* Cervantes-Luevano KE, Caronni N, **Castiello MC**, Fontana E, Piperno GM, Naseem A, Uva P, Bosticardo M, Marcovecchio GE, Notarangelo LD, Cicalese MP, Aiuti A, Villa A, Benvenuti F. *J Allergy Clin Immunol*. 2018 Feb 13. pii: S0091-6749(18)30207-0. doi: 10.1016/j.jaci.2017.11.063. PMID:29447842. ISSN: 00916749
6. *Autonomous role of Wiskott-Aldrich syndrome platelet deficiency in inducing autoimmunity and inflammation.* Sereni L, **Castiello MC**, Marangoni F, Anselmo A, di Silvestre D, Motta S, Draghici E, Mantero S, Thrasher AJ, Giliani S, Aiuti A, Mauri P, Notarangelo LD, Bosticardo M, Villa A. *J Allergy Clin Immunol*. 2018 Feb 6. pii: S0091-6749(18)30201-X. doi: 10.1016/j.jaci.2017.12.1000. PMID:29421274. ISSN: 00916749
7. *Efficacy of lentivirus-mediated gene therapy in an Omenn syndrome recombination-activating gene 2 mouse model is not hindered by inflammation and immune dysregulation.* Capo V, **Castiello MC**, Fontana E, Penna S, Bosticardo M, Draghici E, Poliani LP, Sergi L, Rigoni R, Cassani B, Zanussi M, Carrera P, Uva P, Dobbs K, Sacchetti N, Notarangelo LD, van Til NP, Wagemaker G, Villa A. *J Allergy Clin Immunol*. 2017 Dec 11. pii: S0091-6749(17)31886-9. doi: 10.1016/j.jaci.2017.11.015. PMID:29241731. ISSN: 00916749
8. *Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1.* Schirolli G, Ferrari S, Conway A, Jacob A, Capo V, Albano L, Plati T, **Castiello MC**, Sanvito F, Gennery AR, Bovolenta C, Palchoudhuri R, Scadden DT, Holmes MC, Villa A, Sitia G, Lombardo A, Genovese P, Naldini L. *Sci Transl Med*. 2017 Oct 11;9(411). pii: ean0820. doi: 10.1126/scitranslmed.aan0820. PMID:29021165. ISSN 19466234
9. *Platelets in Wiskott-Aldrich syndrome: Victims or executioners?* Sereni L, **Castiello MC**, Villa A. *J Leukoc Biol*. 2018 Mar;103(3):577-590. doi: 10.1189/jlb.5MR0617-257R. Epub 2017 Dec 29. Review. PMID:28851742. ISSN: 07415400
10. *In vivo chronic stimulation unveils autoreactive potential of Wiskott-Aldrich Syndrome Protein-deficient B cells.* **Castiello MC**, Pala F, Sereni L, Draghici E, Inverso D, Sauer AV, Schena F, Fontana E, Radaelli E, Uva P, Cervantes-Luevano KE, Benvenuti F, Poliani PL, Iannacone M, Traggiai E, Villa A, Bosticardo M. *Front Immunol*. 2017 May 2;8:490. doi: 10.3389/fimmu.2017.00490. eCollection 2017. PMID:28512459. ISSN: 16643224
11. *Intestinal Microbiota sustains inflammation and autoimmunity induced by hypomorphic RAG defects.* Rigoni R, Fontana E, Guglielmetti S, Fosso B, D'Erchia AM, Maina V, Taverniti V, **Castiello MC**, Mantero S, Pacchiana G, Musio S, Pedotti R, Selmi C, Mora JR, Pesole G, Vezzoni P, Poliani PL, Grassi F, Villa A, Cassani B. *J Exp Med*. 2016 Mar 7;213(3):355-75. doi: 10.1084/jem.20151116. ISSN: 00221007
12. *Lentiviral-mediated gene therapy restores B-cell tolerance in Wiskott-Aldrich syndrome patients.* Pala F, Morbach H, **Castiello MC**, Schickel JN, Scaramuzza S, Chamberlain N, Romberg N, Candotti F, Aiuti A, Bosticardo M, Villa A, and Meffre E. *Journal of Clinical Investigation*. 2015 Oct 1;125(10):3941-51. doi: 10.1172/JCI82249. ISSN: 00916749
13. *IL-10 Critically Modulates B Cell Responsiveness in Rankl-/- Mice.* Marrella V, Lo Iacono N, Fontana E, Sobacchi C, Sic H, Schena F, Sereni L, **Castiello MC**, Poliani PL, Vezzoni P, Cassani B, Traggiai E, Villa A. *J Immunol*. 2015 May 1;194(9):4144-53. doi: 10.4049/jimmunol.1401977. ISSN: 00221767
14. *B-cell reconstitution after lentiviral vector-mediated gene therapy in patients with Wiskott-Aldrich syndrome.* **Castiello MC**, Scaramuzza S, Pala F, Ferrua F, Uva P, Brigida I, Sereni L, van der Burg M, Ottaviano G, Albert MH, Roncarolo MG, Naldini L, Aiuti A, Villa A, Bosticardo M. *J Allergy Clin Immunol*. 2015 Sep;136(3):692-702.e2. doi: 10.1016/j.jaci.2015.01.035. ISSN: 00916749
15. *B-cell development and functions and therapeutic options in adenosine deaminase-deficient patients.* Brigida I, Sauer AV, Ferrua F, Giannelli S, Scaramuzza S, Pistoia V, **Castiello MC**, Barendregt BH, Cicalese MP, Casiraghi M, Brombin C, Puck J, Müller K, Notarangelo LD, Montin D, van Montfrans JM, Roncarolo MG, Traggiai E, van Dongen JJ, van der Burg M, Aiuti A. *J Allergy Clin Immunol*. 2014 Mar;133(3):799-806.e10. doi: 10.1016/j.jaci.2013.12.1043. ISSN: 00916749
16. *Wiskott-Aldrich Syndrome protein deficiency perturbs the homeostasis of B-cell compartment in humans.* **Castiello MC**, Bosticardo M, Pala F, Catucci M, Chamberlain N, van Zelm MC, Driessen GJ, Pac M, Bernatowska E, Scaramuzza S, Aiuti A, Sauer AV, Traggiai E, Meffre E, Villa A, and van der Burg M. *J Autoimmun*. 2014 May;50:42-50. doi: 10.1016/j.jaut.2013.10.006. ISSN: 08968411
17. *Wiskott-Aldrich Syndrome protein deficiency in natural killer and dendritic cells affects antitumor immunity.* Catucci M, Zanon I, Draghici E, Bosticardo M, **Castiello MC**, Venturini M, Cesana D, Montini E, Ponzoni M, Granucci F, Villa A. *Eur J Immunol*. 2014 Apr;44(4):1039-45. doi: 10.1002/eji.201343935. ISSN: 00142980
18. *Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich Syndrome.* Aiuti A, Biasco L*, Scaramuzza S*, Ferrua F, Cicalese MP, Baricordi C, Dionisio F, Calabria A, Giannelli S, **Castiello MC**, Bosticardo M, Evangelio C, Assanelli A, Casiraghi M, Di Nunzio S, Callegaro L, Benati C, Rizzardi P, Pellin D, Di Serio M, Schmidt M, Von Kalle C, Gardner J, Mehta N, Neduva V, Dow DJ, Galy A, Miniero R, Finocchi A, Metin A, Banerjee P, Orange J, Galimberti S, Valsecchi MG, Biffi A, Montini E, Villa A, Ciceri F, Roncarolo MG** and Naldini L**. *Science*. 2013 Aug. 23;341(6148):1233151. doi: 10.1126/science.1233151. ISSN: 00368075

19. *Wiskott-Aldrich syndrome protein-mediated actin dynamics control type-I interferon production in plasmacytoid dendritic cells.* Prete F, Catucci M, Labrada M, Gobessi S, **Castiello MC**, Bonomi E, Aiuti A, Vermi W, Cancrini C, Metin A, Hambleton S, Bredius R, Notarangelo LD, van der Burg M, Kalinke U, Villa A, Benvenuti F. *J Exp Med.* 2013 Feb 11;210(2):355-74. doi: 10.1084/jem.20120363. ISSN: 00221007
20. *SOCS1 gene transfer accelerates the transition to heart failure through the inhibition of the gp130/JAK/STAT pathway.* Cittadini A, Monti MG, Iaccarino G, **Castiello MC**, Baldi A, Bossone E, Longobardi S, Marra AM, Petrillo V, Saldamarco L, During MJ, Saccà L, Condorelli G. *Cardiovasc Res.* 2012 Dec 1;96(3):381-90. doi: 10.1093/cvr/cvs261. ISSN: 00086363
21. *Autoimmunity in Wiskott-Aldrich syndrome: an unsolved enigma.* Catucci M, **Castiello MC**, Pala F, Bosticardo M, Villa A. *Front Immunol.* 2012;3:209. doi: 10.3389/fimmu.2012.00209. ISSN: 16643224
22. *Preclinical safety and efficacy of human CD34+ cells transduced with lentiviral vector for the treatment of Wiskott-Aldrich Syndrome.* Scaramuzza S, Biasco L, Ripamonti A, **Castiello MC**, Loperfido M, Draghici E, Jofra Hernandez R, Benedicenti F, Radrizzani M, Salomoni M, Ranzani M, Bartholomae CC, Vicenzi E, Bredius R, Bosticardo M, Schmidt M, von Kalle C, Montini E, Biffi A, Roncarolo MG, Naldini L, Villa A, Aiuti A. *Mol Ther.* 2013 Jan;21(1):175-84. doi: 10.1038/mt.2012.23. ISSN: 15250016
23. *Dendritic cell functional improvement in a preclinical model of lentiviral-mediated gene therapy for Wiskott-Aldrich syndrome.* Catucci M, Prete F, Bosticardo M, **Castiello MC**, Draghici E, Locci M, Roncarolo MG, Aiuti A, Benvenuti F, Villa A. *Gene Ther.* 2011 Dec; 19(12):1150-8. doi: 10.1038/gt.2011.202. ISSN: 09697128
24. *Lentiviral-mediated gene therapy leads to improvement of B-cell functionality in a murine model of Wiskott-Aldrich syndrome.* Bosticardo M, Draghici E, Schena F, Sauer AV, Fontana E, **Castiello MC**, Catucci M, Locci M, Naldini L, Aiuti A, Roncarolo MG, Poliani PL, Traggiai E, Villa A. *J Allergy Clin Immunol.* 2011 Jun;127(6):1376-1384.e5. doi: 10.1016/j.jaci.2011.03.030. ISSN: 00368075
25. *Revertant T lymphocytes in a patient with Wiskott-Aldrich syndrome: analysis of function and distribution in lymphoid organs.* Trifari S, Scaramuzza S, Catucci M, Ponzoni M, Mollica L, Chiesa R, Cattaneo F, Lafouresse F, Calvez R, Vermi W, Medicina D, **Castiello MC**, Marangoni F, Bosticardo M, Doglioni C, Caniglia M, Aiuti A, Villa A, Roncarolo MG, Dupré L. *J Allergy Clin Immunol.* 2010 Feb;125(2):439-448. doi: 10.1016/j.jaci.2009.11.034. ISSN: 00916749
26. *Insulin-like growth factor-1 protects from vascular stenosis and accelerates re-endothelialization in a rat model of carotid artery injury.* Cittadini A, Monti MG, **Castiello MC**, D'Arco E, Galasso G, Sorriento D, Saldamarco L, De Paulis A, Napoli R, Iaccarino G, Saccà L. *J Thromb Haemost.* 2009 Nov;7(11):1920-8. doi: 10.1111/j.1538-7836.2009.03607. ISSN: 15387933

Affiliation to Scientific Societies

2014-present: Associate Member of American Society of Gene and Cell Therapy (ASGCT)
 2019-present: Associate Member of European Society of Gene and Cell Therapy (ESGCT)
 2018: Regular Member of European Society for Immunodeficiencies (ESID)
 2011-2017: Junior Member of European Society for Immunodeficiencies (ESID)
 2010: Trainee Member American Association of Immunologists (AAI)

Editorial Activities

- Scientific Journals: Frontiers in Genome Editing, Review Editor in genome Editing in Blood Disorders, Molecular Therapy
- Public Funding Agencies: The French National Research Agency (ANR, Paris, France)

Language

Italian: mother tongue

English: Proficient User in understanding, speaking and writing skills ([Common European Framework of Reference for Languages](#))

Dissemination and Training activities

- 2015-2018: engaged in the annual fundraising and communication campaign organized by Telethon Foundation aimed at meeting the lay people to respond to any question on rare and genetic diseases.
- 2018: in charge to present the research activities performed in SR-Tiget laboratories to a group of coordinators and volunteers of disease associations.
- 2015-2018: tutoring and supervision for undergraduate and PhD students in Biology and Biotechnology.
- 2018, 2016, 2013: hosting of students from High Schools "Liceo Scientifico Elio Vittorini", "Liceo Scientifico Istituto Maria Consolatrice", "Liceo San Raffaele" (Milan, Italy) for the training "Alternanza Scuola/lavoro" organized by Ministero dell'Istruzione, dell'Università e della Ricerca.
- April 4th 2013: Listener at a debate organized by "Corriere della Sera" in Milan (sala Buzzati) on the "Stamina Method" with M. Andolina and D. Vannoni (clinician and president of Stamina Foundation), experts in the field, patients, their families and different TV-broadcasters.

(https://video.corriere.it/caso-stamina/51de4572-9dc3-11e2-9da0-834a30d18cb2?refresh_ce-cp)


Career break

March 8th 2017 – October 16th 2017: career break for maternity leave.

I authorize the treatment of the personal information in the present document according to the DL 196/03.

January 29th, 2021

Maria Carmina Castiello

A handwritten signature in black ink that reads "Maria Carmina Castiello". The signature is written in a cursive style with a large initial 'M'.